Research Article
The CEDAR Study: A Longitudinal Study of the Clinical Effects of Conventional DMARDs and Biologic DMARDs in Australian Rheumatology Practice
Table 2
Distribution of treatments in the total patient cohort (
= 12,526). Multiple occurrences of the same medication in one individual were counted once.
| cDMARDs | (%) | bDMARDs | (%) |
| Patients with at least one treatment | 11,511 (91.9%) | Patients with at least one treatment | 3,697 (29.5%) |
| Methotrexate | 9,508 (75.9%) | Etanercept | 1,545 (12.3%) | Hydroxychloroquine | 3,527 (28.2%) | Adalimumab | 1,329 (10.6%) | Leflunomide | 3,275 (26.1%) | Tocilizumab | 618 (4.9%) | Sulfasalazine | 2,340 (18.7%) | Abatacept | 481 (3.8%) | Sodium aurothiomalate | 114 (0.9%) | Golimumab | 376 (3.0%) | Azathioprine | 98 (0.8%) | Rituximab | 339 (2.7%) | Cyclosporine | 89 (0.7%) | Certolizumab pegol | 273 (2.2%) | Auranofin | 43 (0.3%) | Infliximab | 68 (0.5%) | Penicillamine | 28 (0.2%) | Anakinra | 3 (<1.0%) | Cyclophosphamide | 10 (0.1%) | ā | ā |
|
|